Current perspectives in bladder cancer management.

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Bladder cancer diagnoses exceed 350,000 globally each year, predominantly transitional cell carcinoma (TCC).
• Smoking and chemical exposure are primary risk factors; painless hematuria is a common symptom requiring urology referral.
• Accurate diagnosis, including staging to exclude muscle invasion, is critical for patient outcomes.

Purpose of the Study:

• To outline the current diagnostic and treatment landscape for bladder cancer.
• To highlight the importance of staging for guiding therapeutic decisions.
• To introduce emerging treatment modalities for non-responsive or advanced bladder cancer.

Main Methods:

• Diagnosis relies on cystoscopy and urine cytology.
• Treatment strategies differentiate between non-muscle invasive and muscle invasive TCC.
• Evaluation of novel interventions like chemohyperthermia and electromotive drug administration is ongoing.

Main Results:

• Non-muscle invasive TCC is managed with transurethral resection, intravesical chemotherapy, or bacillus Calmette-Guérin (BCG) immunotherapy.
• BCG-refractory cases may require cystectomy; limited options exist for surgical candidates.
• Muscle invasive TCC is treated with radical cystectomy or radiotherapy, often preceded by neoadjuvant chemotherapy.
• Metastatic TCC is primarily managed with palliative chemotherapy.

Conclusions:

• Current bladder cancer management involves a multi-modal approach based on disease stage.
• Transurethral resection with intravesical agents or BCG is standard for non-muscle invasive disease.
• Neoadjuvant chemotherapy followed by radical treatment is recommended for muscle invasive TCC.
• Research into novel therapies offers hope for patients with limited treatment options.